Biotie Therapies AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
21 Pages - GLDATA54208
$250.00

Summary

Biotie Therapies AG (Biotie) is a specialized drug development company. It focuses on the development of products for neurodegenerative and psychiatric disorders such as Parkinson's disease, primary sclerosing cholangitis and others. The company’s lead product Selincro, is an orally administered opioid receptor ligand for the treatment of alcohol dependence. Its other products include Tozadenant, 5-HT6 receptor antagonist, monoclonal antibody and nepicastat. The company has collaborations wioth Roche, H. Lundbeck A/S, National Institute of Drug Abuse, and University of Birmingham. The company operates as a subsidiary of Biotie Therapies Corp. Biotie is headquartered in Basel, Switzerland.

Biotie Therapies AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Biotie Therapies AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Synosia Therapeutics Raises US$30 Million In Series C Financing 10
Licensing Agreements 13
Synosia Therapeutics Enters Into Licensing Agreement With UCB For SYN-115 And SYN-118 13
Acquisition 15
Biotie Therapies Acquires Synosia Therapeutics 15
Biotie Therapies AG - Key Competitors 18
Key Employees 19
Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Biotie Therapies AG, Pharmaceuticals & Healthcare, Key Facts 1
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Biotie Therapies AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Biotie Therapies AG, Deals By Therapy Area, 2010 to YTD 2016 8
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Synosia Therapeutics Raises US$30 Million In Series C Financing 10
Synosia Therapeutics Enters Into Licensing Agreement With UCB For SYN-115 And SYN-118 13
Biotie Therapies Acquires Synosia Therapeutics 15
Biotie Therapies AG, Key Competitors 18
Biotie Therapies AG, Key Employees 19

List of Figures
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Biotie Therapies AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838